Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | DTYMK | P23919 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL698803 | 0.85 | USP2 (0.69) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL18294 | 0.85 | USP2 (0.69) | USP2SMN1; SMN2NR1H2HPGDEPHX2 | |
| SCHEMBL1873737 | 0.85 | USP2 (0.51) | USP2SMN1; SMN2DDB1CRBNNR1H2 | |
| SCHEMBL12732309 | 0.85 | USP2 (0.51) | USP2SMN1; SMN2DDB1CRBNNR1H2 | |
| SCHEMBL8431612 | 0.85 | SMN1; SMN2 (0.55) | USP2SMN1; SMN2DDB1CRBNNR1H2 | |
| SCHEMBL16611408 | 0.84 | USP2 (0.50) | USP2SMN1; SMN2DDB1CRBNNR1H2 | |
| SCHEMBL5546526 | 0.83 | USP2 (0.53) | USP2SMN1; SMN2DDB1CRBNNR1H2 | |
| SCHEMBL21567947 | 0.83 | USP2 (0.53) | USP2SMN1; SMN2DDB1CRBNNR1H2 | |
| SCHEMBL17294004 | 0.83 | USP2 (0.53) | USP2SMN1; SMN2DDB1CRBNNR1H2 | |
| SCHEMBL908336 | 0.83 | ALDH1A1 (0.62) | USP2SMN1; SMN2DDB1CRBNDTYMK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4434982-A1 | (S)-2-(2-METHYLAZETIDIN-1-YL)PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | LG Chem, Ltd. (KR) | 2024-09-25 | — | — | EP | disclosed |
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEWYORK | 2023-12-28 | — | — | US | disclosed |
| EP-4217355-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | Forkhead Biotherapeutics, inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023121378-A1 | (S)-2-(2-METHYLAZETIDIN-1-YL)PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 엘지화학 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023121378-A1 | (S)-2-(2-METHYLAZETIDIN-1-YL)PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 엘지화학 | 2023-06-29 | — | — | WO | disclosed |
| WO-2022066938-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FORKHEAD BIOTHERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| WO-2021112626-A1 | NOVEL INDIRUBIN DERIVATIVE AND USE THEREOF | 주식회사 펠레메드 | 2021-06-10 | — | — | WO | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| EP-2334689-A2 | FUSED HETEROCYCLIC COMPOUND | LG Life Sciences Ltd. (KR) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010027236-A2 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010027236-A2 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2010-03-11 | — | — | WO | disclosed |
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| WO-2009082346-A1 | NEW ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS AND USES IN TREATMENTS OF OBESITY AND DIABETES MELLITUS - 087 | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009082346-A1 | NEW ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS AND USES IN TREATMENTS OF OBESITY AND DIABETES MELLITUS - 087 | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FOXO1, FOXO3, GCKR | USP2 2864/4885SMN1; SMN2 495/4885DDB1 1019/4885 |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | F2, PF4, F11 | USP2 3452/4885SMN1; SMN2 4439/4885DDB1 3674/4885 |
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ACACA, ACACB, ACAT1 | USP2 3078/4885SMN1; SMN2 4702/4885DDB1 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.